PSMA3

PSMA3 is the alpha-7 (α7) subunit of the 20S proteasome and functions as a substrate-recognition module for ubiquitin-independent protein degradation (PMID:36291102). Its C-terminal 69-amino-acid region acts as an 'IDP trapper' that preferentially binds intrinsically disordered proteins and, as a recombinant fragment, competitively blocks their degradation by the 20S proteasome, identifying this region as the receptor that delivers disordered substrates for proteolysis (PMID:36291102). One such substrate is the cell-cycle inhibitor p21, whose C-terminal RRLIF box docks directly onto the PSMA3 trapper domain; disrupting this degron extends p21 half-life and produces aberrant cell-cycle progression and enhanced senescence signaling after DNA damage, establishing the trapper as the receptor for a ubiquitin-independent degron [PMID:bio_10.1101_2024.08.29.610237]. Beyond substrate capture, the same C-terminal region is required for 26S proteasome integrity, since its truncation phenocopies loss of the 19S subunit PSMD1 in disrupting 26S assembly (PMID:37371572). PSMA3 additionally associates with splicing factors in both cytoplasm and nucleus and links proteasome function to pre-mRNA splicing regulation in vitro (PMID:22079093). PSMA3 expression is controlled post-transcriptionally by the antisense lncRNA PSMA3-AS1, which stabilizes PSMA3 mRNA and, when delivered via mesenchymal stem cell exosomes, promotes multiple myeloma resistance to proteasome inhibitors (PMID:30610101).

1. 2011 Medium

   Whether the proteasome core particle has roles beyond bulk degradation was unclear; this work showed PSMA3 physically associates with splicing factors and that the 20S proteasome influences pre-mRNA splicing, linking the proteasome to mRNA metabolism.

   Evidence Co-immunoprecipitation, 2D-GE/MS interactome, and in vitro SMN2 splicing assay

   PMID:22079093

   Open questions at the time

   • Does not define which PSMA3 region mediates splicing-factor binding
   • In vitro splicing effect not mapped to a direct catalytic or scaffolding role
   • Physiological relevance of the proteasome–splicing link not established
2. 2022 High

   How the 20S proteasome recognizes substrates without ubiquitin was unknown; this study localized substrate recognition to the PSMA3 C-terminal 69 residues, which selectively bind intrinsically disordered proteins and gate their degradation.

   Evidence Interactome analysis, in vivo Co-IP, cell-free binding, and competitive in vitro 20S degradation assay with recombinant C-terminal fragment

   PMID:36291102

   Open questions at the time

   • Identity of the full IDP substrate repertoire not enumerated
   • Structural basis of disordered-protein recognition not resolved
   • How trapped IDPs are translocated into the catalytic chamber unknown
3. 2023 Medium

   Whether the IDP trapper region has a structural function beyond substrate capture was open; truncating it disrupted 26S integrity comparably to loss of the 19S subunit PSMD1, showing the C-terminus is also required for holoenzyme assembly/stability.

   Evidence CRISPR fluorescent tagging of endogenous PSMB6 and PSMD6, live-cell imaging and colocalization under PSMA3 C-terminal truncation

   PMID:37371572

   Open questions at the time

   • Does not separate the assembly role from the substrate-trapping role at residue level
   • Mechanism by which the C-terminus stabilizes 19S–20S docking not defined
   • Single-lab imaging readout without biochemical reconstitution of 26S assembly
4. 2024 Medium

   It was unknown whether the trapper recognizes a defined degron; mapping identified the p21 C-terminal RRLIF box as the docking motif, and its disruption stabilized p21 and perturbed cell-cycle and senescence responses, establishing PSMA3 as a degron receptor with physiological output.

   Evidence Split-luciferase interaction reporter, p21 mutagenesis, CRISPR editing in HEK293/HeLa, half-life measurement, and cell-cycle/senescence assays (preprint)

   PMID:bio_10.1101_2024.08.29.610237

   Open questions at the time

   • Not yet peer-reviewed
   • Consensus degron beyond p21 RRLIF not generalized
   • Structure of the trapper–degron interface not determined
5. 2019 Medium

   How PSMA3 levels are set and contribute to drug resistance was unclear; this work showed the antisense lncRNA PSMA3-AS1 stabilizes PSMA3 mRNA and that exosomal transfer of PSMA3 from stromal cells confers proteasome-inhibitor resistance in myeloma.

   Evidence Exosome characterization, co-culture transfer, siRNA knockdown, RNA-stability analysis, and xenograft model with siPSMA3-AS1

   PMID:30610101

   Open questions at the time

   • Molecular mechanism by which elevated PSMA3 drives inhibitor resistance not defined
   • RNA duplex model not validated by direct structural mapping
   • Generality across other tumor types not tested

• The structural basis by which the PSMA3 C-terminal trapper distinguishes disordered substrates and degrons, and how this is coupled to translocation and 26S assembly, remains unresolved.
• No high-resolution structure of the trapper–IDP or trapper–degron complex
• Full substrate repertoire of ubiquitin-independent 20S degradation via PSMA3 unknown
• Mechanistic separation of substrate-trapping versus 26S-assembly functions of the C-terminus not achieved